![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
How Effective are Venetoclax + Obinutuzumab?
Venetoclax + Obinutuzumab General Response
The combination of venetoclax and obinutuzumab enables most CLL patients to achieve a multi-year remission, meaning CLL is partially or fully reduced for years.
Venetoclax combined with obinutuzumab often helps most patients achieve undetectable minimal residual disease (uMRD).
Undetectable minimal residual disease means highly sensitive tests find little to no CLL cells in a sample (blood or bone marrow). Patients who achieve uMRD often spend longer periods in remission. The types of tests that screen for minimal residual disease include methods like flow cytometry, polymerase chain reaction (PCR), and next-generation DNA sequencing (NGS).
The sensitivity between uMRD tests may vary. Some tests state you achieve uMRD if there is less than 1 CLL cell per 10,000 white blood cells in the sample. More sensitive tests may increase it to uMRD if there is 1 CLL cell or less per one million white blood cells.
Fixed-duration therapies with venetoclax help patients achieve this deep response of uMRD after treatment. Other CLL treatments, such as continuous-duration BTK inhibitors, often do not achieve uMRD or take years to achieve uMRD.
Venetoclax + Obinutuzumab First-Line Response
Below is the average effectiveness of the one-year combination of venetoclax + obinutuzumab as your first CLL treatment.
| Response Type | Percentage of Patients |
| Patients who experienced undetectable minimal residual disease (uMRD) in a blood sample after completing their one-year treatment course | 75.5% |
| Patients who experienced undetectable minimal residual disease (uMRD) in a bone marrow sample after completing their one-year treatment course | 56.9% |
|
Patients who experienced a complete response (two months after treatment, patients' blood counts returned to normal, and the spleen and lymph nodes were not enlarged) |
49.5% |
|
Patients who experienced a partial response (CLL cells were partially reduced) after treatment |
35.2% |
|
The percentage of people with CLL who experienced any level of response (complete and partial combined) after treatment |
84.7% |
How Long Will Venetoclax + Obinutuzumab Manage CLL? (Progression-Free Survival)
On average, this is how long venetoclax + obinutuzumab will help you achieve progression-free survival (PFS) based on your CLL type. PFS refers to the amount of time the cancer has not progressed and/or patients have been alive since the start of treatment.
| CLL Genetic Status | Years of PFS |
|
Without del(17p)/TP53 mutation |
6.4 |
| With del(17p)/TP53 mutation | 4.3 |
| Mutated IGHV | 7 |
| Unmutated IGHV | 5.4 |
Side Effect Profile of Venetoclax + Obinutuzumab for CLL
The percentage of people with CLL who experience mild-moderate versions of common side effects from VenO is shown below.
| Side Effect | Percentage of Patients Affected |
| Neutropenia | 60% |
| Diarrhea | 28% |
| Fatigue | 21% |
For more information on the above side effects, you can visit this guide's Side Effects Management section.
For more information on side effects you may get from VenO, visit the Venclexta Medication Guide.
Financial Resources for Venetoclax + Obinutuzumab
Click here to locate financial resources for venetoclax. For additional resources, click here to visit the financial support section of the guide.